{"title":"TIL 终结：追踪采用细胞疗法期间 T 细胞克隆型的动态变化","authors":"Anthony C. Buzzai, Thomas Tüting","doi":"10.1016/j.immuni.2024.09.012","DOIUrl":null,"url":null,"abstract":"Understanding the factors that lead to the therapeutic success of adoptive cell therapies using tumor-infiltrating lymphocytes (TIL-ACT) will improve current treatment protocols. In this issue of <em>Immunity</em>, Chiffelle et al. comprehensively compare the dynamics of CD8<sup>+</sup> T cell clonotypes during the course of ACT between responding and non-responding patients.","PeriodicalId":13269,"journal":{"name":"Immunity","volume":"3 1","pages":""},"PeriodicalIF":25.5000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TIL the end: Tracking T cell clonotype dynamics during adoptive cell therapy\",\"authors\":\"Anthony C. Buzzai, Thomas Tüting\",\"doi\":\"10.1016/j.immuni.2024.09.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Understanding the factors that lead to the therapeutic success of adoptive cell therapies using tumor-infiltrating lymphocytes (TIL-ACT) will improve current treatment protocols. In this issue of <em>Immunity</em>, Chiffelle et al. comprehensively compare the dynamics of CD8<sup>+</sup> T cell clonotypes during the course of ACT between responding and non-responding patients.\",\"PeriodicalId\":13269,\"journal\":{\"name\":\"Immunity\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":25.5000,\"publicationDate\":\"2024-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.immuni.2024.09.012\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.immuni.2024.09.012","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
了解导致使用肿瘤浸润淋巴细胞（TIL-ACT）的采纳细胞疗法取得治疗成功的因素将改善目前的治疗方案。在本期《免疫》（Immunity）杂志上，Chiffelle 等人全面比较了有应答和无应答患者在采用 ACT 治疗过程中 CD8+ T 细胞克隆型的动态变化。
TIL the end: Tracking T cell clonotype dynamics during adoptive cell therapy
Understanding the factors that lead to the therapeutic success of adoptive cell therapies using tumor-infiltrating lymphocytes (TIL-ACT) will improve current treatment protocols. In this issue of Immunity, Chiffelle et al. comprehensively compare the dynamics of CD8+ T cell clonotypes during the course of ACT between responding and non-responding patients.
期刊介绍：
Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
